| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CHI3L1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
1. **"CHI3L1 (YKL-40) is a biomarker of inflammation and tissue remodeling in lung cancer"**
- 作者：Lee C.M. 等
- 摘要：研究利用CHI3L1特异性抗体检测肺癌患者血清及组织中的表达水平，发现其与炎症微环境及肿瘤侵袭性相关，提示其作为预后标志物的潜力。
2. **"Therapeutic targeting of CHI3L1 with monoclonal antibodies inhibits tumor progression in preclinical models"**
- 作者：Chen T. 等
- 摘要：开发了一种靶向CHI3L1的单克隆抗体，通过抑制CHI3L1与IL-13Rα2的相互作用，在结直肠癌小鼠模型中显著减少肿瘤生长和转移。
3. **"CHI3L1 antibody blockade attenuates fibrosis in a mouse model of idiopathic pulmonary fibrosis"**
- 作者：Zhou Y. 等
- 摘要：通过抗CHI3L1抗体阻断实验，证明其可减少肺纤维化模型中的胶原沉积和炎症细胞浸润，机制涉及调控巨噬细胞活化及TGF-β通路抑制。
4. **"Structural insights into CHI3L1-antibody interaction reveal novel epitopes for diagnostic applications"**
- 作者：Kim S. 等
- 摘要：通过X射线晶体学解析CHI3L1蛋白与抗体的结合位点，验证了高亲和力抗体在慢性炎症性疾病诊断中的高灵敏度和特异性应用价值。
CHI3L1 (Chitinase-3-like protein 1), also known as YKL-40. is a secreted glycoprotein encoded by the CHI3L1 gene. It belongs to the mammalian chitinase-like protein family but lacks enzymatic activity due to mutations in its chitin-binding domain. CHI3L1 is implicated in inflammation, tissue remodeling, and pathological processes such as cancer, fibrosis, and metabolic disorders. Elevated levels of CHI3L1 are observed in conditions like asthma, rheumatoid arthritis, Alzheimer’s disease, and various cancers (e.g., glioblastoma, breast, and colorectal cancer), where it promotes cell proliferation, angiogenesis, and resistance to apoptosis.
Antibodies targeting CHI3L1 are essential tools for studying its biological roles and therapeutic potential. They enable detection of CHI3L1 expression in tissues or bodily fluids, aiding in disease diagnosis and prognosis. In research, these antibodies help elucidate CHI3L1’s interaction with signaling pathways, such as MAPK/ERK and Wnt/β-catenin, which drive disease progression. Therapeutically, anti-CHI3L1 antibodies are being explored to block its pro-inflammatory or pro-tumorigenic effects. For example, preclinical studies show that neutralizing CHI3L1 antibodies can inhibit tumor growth and metastasis in cancer models or reduce inflammation in autoimmune diseases. However, challenges remain in optimizing specificity and delivery for clinical applications. Overall, CHI3L1 antibodies hold promise as both diagnostic biomarkers and targeted therapies, reflecting the protein’s dual role in homeostasis and disease.
×
